. 2023 Jun 2;13:8998. doi: 10.1038/s41598-023-35764-7

Table 3.

Plasma lipids, HDL composition, and HDL-mediated cholesterol efflux according to the molecular type of BC.

	LA	LB	HER2	TN	P
n	46	65	26	26
Age (years)	60 (52–64)	54 (48–63)	55 (49–61)	53 (41–61)	0.107
BMI (kg/m²)	27 (24–31)	28 (25–31)	27 (24–31)	27 (24–30)	0.793
TC (mg/dL)	193 (162–228)	173 (155–205)	173 (151–193)	198 (173–214)	0.022^#
TG (mg/dL)	103 (66–139)	84 (67–110)	82 (63–105)	102 (91–134)	0.026^$
apoB (mg/dL)	129 (90–151)	98 (81–123)	100 (81–127)	134 (102–158)	0.005^$
HDLc (mg/dL)	41 (34–49)	42 (33–53)	42 (32–52)	42 (36–50)	0.997
LDLc (mg/dL)	123 (99––155)	111 (90–138)	117 (85–134)	127 (98–148)	0.116
VLDLc (mg/dL)	21 (13–28)	17 (13–22)	16 (13–21)	20 (18–27)	0.026^$
non-HDLc (mg/dL)	147 (121–184)	129 (104–162)	135 (105–151)	155 (130–174)	0.013^$
TC/apoB	1.7 (1.4–2.0)	1.8 (1.5–2.1)	1.8 (1.5–2.0)	1.5 (1.3–2.0)	0.313
TG/HDLc	2.3 (1.3–3.4)	1.9 (1.3–3.1)	1.7 (1.3–3.2)	2.5 (2.0–3.4)	0.358
HDL-TC (mg/dL)	39 (30–49)	40 (27–52)	41 (29–49)	45 (23–58)	0.886
HDL-TG (mg/dL)	15 (12–34)	17 (11–62)	13 (11–18)	24 (14–91)	0.055
HDL-PL (mg/dL)	90 (71–119)	90 (77–121)	104 (82–124)	96 (77–117)	0.435
HDL-apoA-I (mg/dL)	114 (83–142)	108 (76–150)	108 (86–139)	107 (90–123)	0.894
24HC (ng/mL)	28 (22–49)	36 (23–78)	35 (28–58)	35 (24–88)	0.681
25HC (ng/mL)	7.3 (5.6–9.2)	8.3 (6.4–9.8)	6.6 (4.6–9.4)	6.0 (4.5–7.6)	0.110
27HC (ng/mL)	5.8 (4.5–10.6)	10.9 (4.4–13.8)	7.2 (4.7–14.6)	5.7 (4.1–14.2)	0.580
¹⁴C-cholesterol efflux (%)	14 (10–17)	12 (9–19)	13 (8–15)	11 (8–18)	0.921

HER2

Age (years)

(52–64)

(48–63)

(49–61)

(41–61)

0.107

BMI (kg/m²)

(24–31)

(25–31)

(24–31)

(24–30)

0.793

TC (mg/dL)

193

(162–228)

173

(155–205)

173

(151–193)

198

(173–214)

0.022^#

TG (mg/dL)

103

(66–139)

(67–110)

(63–105)

102

(91–134)

0.026^$

apoB (mg/dL)

129

(90–151)

(81–123)

100

(81–127)

134

(102–158)

0.005^$

HDLc (mg/dL)

(34–49)

(33–53)

(32–52)

(36–50)

0.997

LDLc (mg/dL)

123

(99––155)

111

(90–138)

117

(85–134)

127

(98–148)

0.116

VLDLc (mg/dL)

(13–28)

(13–22)

(13–21)

(18–27)

0.026^$

non-HDLc (mg/dL)

147

(121–184)

129

(104–162)

135

(105–151)

155

(130–174)

0.013^$

TC/apoB

1.7

(1.4–2.0)

1.8

(1.5–2.1)

1.8

(1.5–2.0)

1.5

(1.3–2.0)

0.313

TG/HDLc

2.3

(1.3–3.4)

1.9

(1.3–3.1)

1.7

(1.3–3.2)

2.5

(2.0–3.4)

0.358

HDL-TC (mg/dL)

(30–49)

(27–52)

(29–49)

(23–58)

0.886

HDL-TG (mg/dL)

(12–34)

(11–62)

(11–18)

(14–91)

0.055

HDL-PL (mg/dL)

(71–119)

(77–121)

104

(82–124)

(77–117)

0.435

HDL-apoA-I (mg/dL)

114

(83–142)

108

(76–150)

108

(86–139)

107

(90–123)

0.894

24HC (ng/mL)

(22–49)

(23–78)

(28–58)

(24–88)

0.681

25HC (ng/mL)

7.3

(5.6–9.2)

8.3

(6.4–9.8)

6.6

(4.6–9.4)

6.0

(4.5–7.6)

0.110

27HC (ng/mL)

5.8

(4.5–10.6)

10.9

(4.4–13.8)

7.2

(4.7–14.6)

5.7

(4.1–14.2)

0.580

¹⁴C-cholesterol efflux (%)

(10–17)

(9–19)

(8–15)

(8–18)

0.921

Plasma lipids were determined by enzymatic colorimetric methods and apoB by immunoturbidimetry. HDLc was determined after precipitation of lipoproteins containing apoB; non-HDLc was calculated as TC-HDLc. Oxysterols were quantified in isolated HDL by gas chromatography-mass spectrometry (GC–MS). The cholesterol efflux was determined in BMDM overloaded with ¹⁴C-cholesterol and acetylated LDL, utilizing 50 µg/mL of HDL as a cholesterol acceptor.

CTR, control women; BC, breast cancer; BMI, body mass index; TC, total cholesterol; TG, triglycerides; apoB, apolipoprotein B; HDLc, high-density lipoprotein cholesterol; LDLc, low density lipoprotein cholesterol; VLDLc, very low density lipoprotein cholesterol; PL, phospholipids; apoA-I, apolipoprotein A-I; 24HC, 24-hydroxycholesterol (CTR, n = 82; BC, n = 82); 25HC, 25-hydroxycholesterol (CTR, n = 82; BC, n = 82); 27HC, 27-hydroxycholesterol (CTR, n = 81; BC, n = 80). Comparisons were made using the Kruskall-Wallis test with a significance of 0.05. Data shown in median and interquartile ranges (25–75%). LA, luminal A; LB, luminal B; TN, triple negative. ^# in comparison to LA, LB, and HER2; ^$ in comparison to LB and HER2.